Home › Compare › GUESF vs ABBV
GUESF yields 2000000.00% · ABBV yields 3.06%● Live data
📍 GUESF pulled ahead of the other in Year 1
Combined, GUESF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GUESF + ABBV for your $10,000?
GuestLogix Inc. provides retail and payment technology solutions to the passenger travel industry. The company offers point-of-sale (POS) hardware solutions comprising mobile, POS device, and inflight entertainment systems; retail platform solutions; and payment processing technology, as well as OnTouch destination merchandising solutions. It also provides ancillary insights services, such as out-of-the-box reporting suites, enterprise reporting toolsets, and advanced analytics; and travel retail performance management services consisting of operational process development, outsourced retail management, and retail model development services. In addition, the company offers GuestPass Ticketing, a ticketing solution that enables travel operators to facilitate ticketing services across multiple access points; and t-Retail Platform, which provides destination-based content for travel operators to use in the booking path. It primarily serves customers in North America, Europe, South America, Africa, and Asia. The company is headquartered in Toronto, Canada.
Full GUESF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.